RT Journal Article
SR Electronic
T1 Ribavirin antiviral combination therapy in COVID 19, a single-center experience
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.24.22274149
DO 10.1101/2022.04.24.22274149
A1 Singh, Budha O
A1 Chikara, Gaurav
A1 Panda, Prasan Kumar
A1 Bahurupi, Yogesh Arvind
A1 Saha, Sarama
A1 Pai, Venkatesh S.
YR 2022
UL http://medrxiv.org/content/early/2022/04/25/2022.04.24.22274149.abstract
AB Background COVID 19 infection has a similar clinical spectrum of disease presentation such as SARS and MERS in the past. These led to the assumption of the possibility to treat COVID 19 infection with antivirals which had been used to treat SARS and MERS.Methods A retrospective analysis was done on the data of SEV COVID Trial in symptomatic adult patients of COVID 19 infection with objectives to explore whether ribavirin antiviral combinations reduces the need of both noninvasive and invasive ventilators in treatment of COVID 19 infections.Results The patients were categorized as “Cohort A” consisting of 40 patients and “Cohort B” of 61 patients as Cohort A being the group of patients who received the standard therapy and Cohort B the group of patients who received the ribavirin combination therapy.Conclusion The study concluded that there was no statistically significant difference in regard to the need of noninvasive ventilation and invasive ventilation and also the development of multi-organ dysfunction in between the two Cohorts. Also, with progress of time, the proportion of patients with single organ dysfunctions in the two cohorts showed gradual recovery without any statistically significant differences.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCTRI/2020/06/025575Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Ethics Committee, AIIMS, Rishikesh (Letter No- AIIMS/IEC/21/526. Date: 09/10/2021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors